Literature DB >> 32715321

Novel Therapeutic Approaches of Ion Channels and Transporters in Cancer.

Ana Ramírez1, Janice García-Quiroz2, Luis Aguilar-Eslava3, Yesennia Sánchez-Pérez4, Javier Camacho5.   

Abstract

The expression and function of many ion channels and transporters in cancer cells display major differences in comparison to those from healthy cells. These differences provide the cancer cells with advantages for tumor development. Accordingly, targeting ion channels and transporters have beneficial anticancer effects including inhibition of cancer cell proliferation, migration, invasion, metastasis, tumor vascularization, and chemotherapy resistance, as well as promoting apoptosis. Some of the molecular mechanisms associating ion channels and transporters with cancer include the participation of oxidative stress, immune response, metabolic pathways, drug synergism, as well as noncanonical functions of ion channels. This diversity of mechanisms offers an exciting possibility to suggest novel and more effective therapeutic approaches to fight cancer. Here, we review and discuss most of the current knowledge suggesting novel therapeutic approaches for cancer therapy targeting ion channels and transporters. The role and regulation of ion channels and transporters in cancer provide a plethora of exceptional opportunities in drug design, as well as novel and promising therapeutic approaches that may be used for the benefit of cancer patients.
© 2020. Springer Nature Switzerland AG.

Entities:  

Keywords:  Cancer; Immunotherapy; Ion channels; Mitochondria; Oxidative stress; Toxins; Transporters

Mesh:

Substances:

Year:  2022        PMID: 32715321     DOI: 10.1007/112_2020_28

Source DB:  PubMed          Journal:  Rev Physiol Biochem Pharmacol        ISSN: 0303-4240            Impact factor:   5.545


  27 in total

Review 1.  TRP channels as mediators of oxidative stress.

Authors:  Barbara A Miller; Wenyi Zhang
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

2.  Drug Repurposing from an Academic Perspective.

Authors:  Tudor I Oprea; Julie E Bauman; Cristian G Bologa; Tione Buranda; Alexandre Chigaev; Bruce S Edwards; Jonathan W Jarvik; Hattie D Gresham; Mark K Haynes; Brian Hjelle; Robert Hromas; Laurie Hudson; Debra A Mackenzie; Carolyn Y Muller; John C Reed; Peter C Simons; Yelena Smagley; Juan Strouse; Zurab Surviladze; Todd Thompson; Oleg Ursu; Anna Waller; Angela Wandinger-Ness; Stuart S Winter; Yang Wu; Susan M Young; Richard S Larson; Cheryl Willman; Larry A Sklar
Journal:  Drug Discov Today Ther Strateg       Date:  2011

3.  Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.

Authors:  Antonio Omuro; Kathryn Beal; Katharine McNeill; Robert J Young; Alissa Thomas; Xuling Lin; Robert Terziev; Thomas J Kaley; Lisa M DeAngelis; Mariza Daras; Igor T Gavrilovic; Ingo Mellinghoff; Eli L Diamond; Andrew McKeown; Malbora Manne; Andrew Caterfino; Krishna Patel; Linda Bavisotto; Greg Gorman; Michael Lamson; Philip Gutin; Viviane Tabar; Debyani Chakravarty; Timothy A Chan; Cameron W Brennan; Elizabeth Garrett-Mayer; Rashida A Karmali; Elena Pentsova
Journal:  J Clin Oncol       Date:  2018-04-23       Impact factor: 44.544

4.  Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors.

Authors:  M S Cairo; S Siegel; N Anas; L Sender
Journal:  Cancer Res       Date:  1989-02-15       Impact factor: 12.701

5.  The platinum (II) complex [Pt(O,O'-acac)(γ-acac)(DMS)] alters the intracellular calcium homeostasis in MCF-7 breast cancer cells.

Authors:  Antonella Muscella; Nadia Calabriso; Carla Vetrugno; Francesco Paolo Fanizzi; Sandra Angelica De Pascali; Carlo Storelli; Santo Marsigliante
Journal:  Biochem Pharmacol       Date:  2010-09-18       Impact factor: 5.858

6.  A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines.

Authors:  P Lissoni; R Bucovec; F Malugani; A Ardizzoia; S Villa; G S Gardani; M Vaghi; G Tancini
Journal:  Anticancer Res       Date:  2002 Mar-Apr       Impact factor: 2.480

Review 7.  Kv10.1 K(+) channel: from physiology to cancer.

Authors:  Halima Ouadid-Ahidouch; Ahmed Ahidouch; Luis A Pardo
Journal:  Pflugers Arch       Date:  2016-01-08       Impact factor: 3.657

Review 8.  NFAT proteins: emerging roles in cancer progression.

Authors:  Maria Mancini; Alex Toker
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

9.  Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241.

Authors:  Guido Gessner; Stefan H Heinemann
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

10.  Expression of eag1 channel associated with the aggressive clinicopathological features and subtype of breast cancer.

Authors:  Guang-Xu Liu; Yun-Cui Yu; Xiang-Ping He; Sheng-Nan Ren; Xue-Dong Fang; Fen Liu; Yan He
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01
View more
  3 in total

Review 1.  Combinations of Calcitriol with Anticancer Treatments for Breast Cancer: An Update.

Authors:  Mariana Segovia-Mendoza; Janice García-Quiroz; Lorenza Díaz; Rocío García-Becerra
Journal:  Int J Mol Sci       Date:  2021-11-25       Impact factor: 5.923

Review 2.  Ion Channels in Endometrial Cancer.

Authors:  Bruna Pasqualotto Costa; Fernanda Bordignon Nunes; Francini Corrêa Noal; Gisele Branchini
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

3.  Ion Channels and Transporters in Autophagy.

Authors:  Ruoxi Zhang; Rui Kang; Daniel J Klionsky; Daolin Tang
Journal:  Autophagy       Date:  2021-03-03       Impact factor: 16.016

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.